Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Resources>Posters

  Posters

Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
Daniel Brown (1), Niklas Larsson (2), Ola Fjellström (3), Anders Johansson (3), Sara Lundqvist (2), Johan Brengdahl (2), and Richard J. Isaacs (1)

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds.

Mixtures Analysis of Complex Mixtures
Michael Bernstein; Carlos Cobas; Santi Domínguez; Manuel Pérez; Agustín Barba

We describe an NMR method to quantify mixture components in wine, edible oils, etc. The method is fully customizable, and amenable to high throughput operation.

Novel Gpr39 Agonists: Correlation Of Binding Affinity Using Label-Free Back-Scattering Interferometry With Potency In Functional Assays
Daniel Brown (1), Niklas Larsson (2), Ola Fjellström (3), Anders Johansson (3), Sara Lundqvist (2), Johan Brengdahl (2), and Richard J. Isaacs (1)

We describe the application of back-scattering interferometry (BSI) to the characterization of small molecule ligand binding to human GPR39 (a GPCR targeted for type-2 diabetes therapy) overexpressed in crude membrane fractions in free solution, including how BSI-derived affinity and functional assay-derived potency correlate for compounds of varying scaffolds

GC-MS/MS ANALYSIS OF BENZODIAZEPINES USING ANALYTE PROTECTANTS
Jeremy Matthews, Alex Chen, Flavio Bedini

Purpose: Assess the feasibility of using analyte protectants to improve the analysis of benzodiazepines.

Targeted cancer therapy based on blocking the expression of genes and small doses of oxaliplatin.
Bavykin A.S.1, Korotaeva A.A.1, Poyarkov S.V.2, Syrtsev A.V.1, Karpukhin A.V.1

The major drawbacks of the prescribed chemotherapy, are still remain the significant side effects and drug - resistance. Even targeted chemotherapy by means of specific antibodies do not always help to solve these complications. Our purpose was to identify potential biological targets associated with the development of drug resistance and to develop a specific method of suppressing the viability of cancer cells exposed to low doses of standard chemotherapy.

Inverted Y Approach to Lumbosacral region - Analysis of 525 cases over 10 years
Dr Krishna Kumar and Dr Renjith Kumar

Traditional approach to lumosacral region utilizes midline incision, which often requires long incision to get sufficient exposure. We describe our experience with inverted Y approach to lumbosacral junction.

Evaluation of an automated SPE method for samples derived from capillary microsampling
Paul-Gerhard Lassahn1, Petra Lombardi1, Winfried Wagner-Redeker1, Marie-Claude Robaudi-Fraschini2, Reto Bolliger3, Guenter Boehm3

In this poster we describe an automated SPE procedure using small, single use cartridges in a modified PAL System liquid handler for the analysis of samples derived from capillary microsampling. Results are compared to results obtained from identical samples processed manually by protein precipitation.

LC/MS/MS Quantitation of Eicosapentaenoic Acid in Rat Plasma
Rachel Sun, Jordan Nally, Tim Shoaf

Eicosapentaenoic acid (EPA) is an omega-3 fatty acid, which has been documented to be important in biochemical and physiological processes including inflammatory response, blood clotting and the immune system. Eicosapentaenoic acid (EPA) appears in different forms in the blood including triglyceride, ethyl ester, or free acid. In this work we presented an LC/MS/MS method to quantitate the total eicosapentaenoic acid in rat plasma with a 96-well plate format.

Comparison of Dissociated Phoria Measuring Methods. Repeatability and Reliability
Ane Murueta-Goyena Larrañaga

The aim of this study is to determine the reliability and compare reproducibility of different dissociated phoria measure tests.

<< 1 2 3 4 5 6 >>
Showing Results 11 - 20 of 53
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!